絞り込み

16555

広告

日欧で低負担実現 初の大規模協力 (毎日新聞)

日本と欧州が協力して水星を調査する「ベピ・コロンボ計画」の探査機2機が19日(日本時間20日)、南米・仏領ギアナのクールー宇宙基地から欧州のアリアン5ロケットで...

  1. 変わり果てた「山水画」の世界に、中国の開...
  2. 石炭火力、保険引き受け停止相次ぐ - 日...
  3. 1-617【ミドル記事】★外国語(トルコ...
  4. 「人種差別に遺伝学使うな」米学会、白人至...

ニュース一覧

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

著者 Yang X , Li Y , Sun Y , Zhang M , Guo C , Mirza IA , Li YQ
Dig Dis Sci.2017 Dec 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (217view , 0users)

Full Text Sources

Medical

Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection in Japan. The healing rate of GERD and gastric ulcers by vonoprazan is more than 95 and 90%, respectively; also, it is effective in curing PPI-resistant GERD. It increases H. pylori eradication rate to more than 88% as part of both first-line and second-line therapy. It is also effective in the eradication of clarithromycin-resistant H. pylori strains. All of these short-term studies show vonoprazan is safe and well-tolerated. As a safe and effective acid inhibitor, vonoprazan might be a novel alternative in the treatment of acid-related diseases.
PMID: 29282636 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード